Novo Nordisk is offering self-paying U.S. patients who are new to its weight-loss drug Wegovy their first month of medicine for $199 until June 30, the Danish drugmaker said on Thursday, aiming to curb sales of compounded drugs or copies of the drug.

Danish pharmaceutical company Novo Nordisk, maker of blockbuster weight loss drug Wegovy, said Friday its CEO was stepping down by “mutual agreement” with the company’s board of directors, citing “recent market challenges” and a steep decline in the company’s share price.

Novo Nordisk A/S is selling its blockbuster weight-loss drug Wegovy to new patients at $199 for the first month as easy access to cheaper copycats comes to an end.